Physician profile
Michael Herman
NPI 1780002063
$2,352.09
in general payments reported to CMS, 2019-2025
17 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $18.10 · 2021: $126 · 2022: $72.92 · 2023: $387 · 2024: $1,216 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,073 · Consulting Fee: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,072.70 |
| Consulting Fee | $750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $860.22 | 2019-2025 | |
| Samsung Bioepis Co., LTD. | $750.00 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $169.26 | 2021-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $96.14 | 2021-2025 | Eohilia, Entyvio |
| Pfizer INC. | $76.32 | 2023-2024 | |
| Ferring Pharmaceuticals INC. | $75.94 | 2023-2025 | Rebyota, Clenpiq |
| Celgene Corporation | $57.55 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $53.13 | 2024 | Stelara |
| Braintree Laboratories, INC. | $36.81 | 2023-2025 | Sutab, Suflave |
| Merck Sharp & Dohme LLC | $36.00 | 2022-2024 | Zinplava, Dificid |
| Lilly USA, LLC | $33.94 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $27.44 | 2023-2024 | Ibsrela |
| Therapeuticsmd, INC. | $19.90 | 2019 | |
| Genzyme Corporation | $16.35 | 2023 | |
| Phathom Pharmaceuticals, INC. | $15.10 | 2024 | Voquezna |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $14.10 | 2023 | |
| Organon LLC | $13.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Herman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.